## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS**
- Source: MarketBeat | 20251207T042136 | Neutral | Relevance: 99%
-  Kennedy Capital Management LLC reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 12.2% in the second quarter, now holding 132,045 shares valued at $5.22 million. Despite insider selling activity, Ionis Pharmaceuticals exceeded revenue and EPS expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $84.15. The article details institutional ownership changes, insider sales, and recent financial performance.

**2. Hsbc Holdings PLC Purchases 33,461 Shares of Ionis Pharmaceuticals, Inc. $IONS**
- Source: MarketBeat | 20251206T110943 | Somewhat-Bullish | Relevance: 98%
- Hsbc Holdings PLC has increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 44.7%, acquiring an additional 33,461 shares to bring its total to 108,294 shares valued at approximately $4.29 million. This move comes as several analysts have upgraded Ionis and raised their price targets, despite recent insider selling totaling $37.2 million. Institutional ownership of Ionis Pharmaceuticals remains high at 93.86%, and the stock currently holds a "Moderate Buy" rating with a consensus target price of $84.15.

**3. Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn?**
- Source: Trefis | 20251208T080943 | Neutral | Relevance: 98%
- The article discusses the recent surge in Ionis Pharmaceuticals stock and raises questions about its potential performance during market downturns. It speculates on whether the stock can maintain its value if market conditions become less favorable.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | HC Wainwright & | $110 | $100 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 21 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Valuation stretched: PEG 25.7x requires aggressive growth execution.
3. Elevated short interest (11.6%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (1 raises, avg +10%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $13.2B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 11.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 1.0% to -0.9% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.93% (CS: 46) | Neutral |
| RSI_14 | 66.6 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.057x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.707x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $81.51
- **Stop Loss:** $76.35 (6.3% risk)
- **Target:** $86.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 96
- **Position Value:** $7,824.96
- **Portfolio %:** 7.82%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*